Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension

References

• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA303, 2043–2050 (2010).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (Greenwich)4, 393–404 (2002).
   PubMedGoogle Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Elijovich FD, Laffer CD. A role for single-pill triple therapy in hypertension. Ther. Adv. Cardiovasc. Dis.3, 231–240 (2009).
   PubMedGoogle Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA202, 1028–1034 (1967).
   PubMed Web of Science ®Google Scholar
• Exforge HCT (package insert). Novartis Pharmaceuticals Corporation, NJ, USA (2009).
   Google Scholar
• Tribenzor (package insert). Daiichi Sankyo, Inc., NJ, USA (2010).
   Google Scholar
• Chrysant SG, Weber MA, Wang AC et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens.17, 252–259 (2004).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther.30, 587–604 (2008).
   PubMed Web of Science ®Google Scholar
• Lacy CF, Armstrong LL, Goldman MP et al.Drug Information Handbook (14th Edition). Lexi-Comp, OH, USA (2006).
   Google Scholar
• Physician’s Desk Reference (62nd Edition). Thomson PDR, NJ, USA (2008).
   Google Scholar
• Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. Suppl.19, S21–S32 (2001).
   PubMedGoogle Scholar
• Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J. Clin. Pharmacol.41, 515–527 (2001).
   PubMed Web of Science ®Google Scholar
• Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol.285, 181–188 (1995).
   PubMed Web of Science ®Google Scholar
• Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan–amlodipine combination. Vasc. Health Risk Manag.4, 653–664 (2008).
   PubMedGoogle Scholar
• Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin. Pharmacokinet.22, 22–31 (1992).
   PubMed Web of Science ®Google Scholar
• Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs41, 478–505 (1991).
   PubMed Web of Science ®Google Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension43, 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc. Health Risk Manag.2, 401–409 (2006).
   PubMedGoogle Scholar
• Oparil S, Melino M, Lee J et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINTY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther.32, 1252–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Oparil S, Melino M et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens. (Greenwich)11, 475–482 (2009).
   PubMed Web of Science ®Google Scholar
• Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig.29, 381–391 (2009).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Sachson RA, Qian C et al. Efficacy and onset of antihypertensive effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and Type 2 diabetes [PO-233]. J. Clin. Hypertens.12(Suppl. 1), A111–A112 (2010).
   Google Scholar
• Weir MR, Weber MA, Nesbitt SD et al. Rationale and design of the BP CRUSH study: evaluation the efficacy and safety of amlodipine/olmesartan medoxomil in patients who are non-responders to antihypertensive monotherapy (abstract P-297). J. Clin. Hypertens.11, A136–A137 (2009).
   Google Scholar
• Weir M, Hseuh W, Nesbitt S et al. Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (abstract LB-PO-08).
   Google Scholar
• Ram VS, Sachson RA, Qian C et al. Effects of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension, Type 2 diabetes and metabolic syndrome (abstract PO-193). J. Clin. Hypertens.21(Suppl. 1), A96 (2010).
   Google Scholar
• Chrysant SG, Neutel JM, Qian C et al. The safety and tolerability profile of an amlodipine- and olmesartan medoxomil-based titration regimen in patients with hypertension and Type 2 diabetes (abstract PO-204). J. Clin. Hypertens.12(Suppl. 1), A100–A101 (2010).
   Google Scholar
• Gradman AH, Basile JN, Carter BL et al. Combination therapy in hypertension. J. Am. Soc. Hypertens.4, 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med.122, 290–300 (2009).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijisq L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens.22, 847–857 (2004).
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet363, 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Nasser SA, Lai Z, O’Connor S et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr. Hypertens. Rep.10, 398–404 (2008).
   PubMed Web of Science ®Google Scholar
• Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther. Adv. Cardiovasc. Dis.4, 119–127 (2010).
   PubMedGoogle Scholar
• Dusing R. Optimizing blood pressure control through the use of fixed combinations. Vasc. Health Risk Manag.6, 321–325 (2010).
   PubMedGoogle Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension55, 399–407 (2010).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar